pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›PROSTIN VR PEDIATRIC
drug · small molecule
save

PROSTIN VR PEDIATRIC

updated 3mo ago
by $PFE PFIZER INC🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 4
  • drugProstin VR81 co-mentions · 21 sources
  • tagApproval80 co-mentions · 20 sources
  • drugalprostadil41 co-mentions · 21 sources
  • tagRecall1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.

targets

Prostaglandin E2 receptor EP2 subtypeProstaglandin E2 receptor EP1 subtype

all catalysts(0)

nothing on the calendar yet

Trials studying PROSTIN VR PEDIATRIC

  • phase3ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failurenot yet recruitingn=600
  • phase2A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKIterminatedn=132

News(0)

no news has mentioned this drug yet

brand
PROSTIN VR PEDIATRIC
trade names
Alprostadil, Caverject, Caverject impulse, Edex, Prostin vr, Prostin vr pediatric
generic
ALPROSTADIL
MOA
Prostanoid EP2 receptor agonist; Prostanoid EP1 receptor agonist
indication
INDICATIONS AND USAGE PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care.
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 20m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?